Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 523-528, December 2009

Prognostic factors in AML in relation to (ab)normal karyotype

  • Richard M. Stone, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 617 32 2214; Fax: +1 617 632 2933.

Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Room M1b-17, Boston MA 02115-6084, USA

Acute myeloid leukaemia (AML) is a complicated, heterogeneous disease and the prognostic factors may be useful in deciding upon appropriate therapy. Cytogenetic testing at diagnosis yields critical prognostic information, but more refinement in prognosis is required. Within cytogenetic subgroups, further important subgroup definitions are possible based on the mutation status and expression analysis of genes such as C-KIT, FLT3, NPM1 and CEBPA, although defining therapies based on such mutations remains controversial.

Keywords: acute myeloid leukaemia, AML, cytogenetic, FLT3, gene expression, karyotype, NPM1, prognosis, mutation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(09)00037-1

doi:10.1016/j.beha.2009.07.003

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 523-528, December 2009

Article Tools